Teruo Ishihara

Learn More
Background. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended,(More)
OBJECTIVE Interstitial lung disease in patients with colorectal cancer during chemotherapy combined with bevacizumab is rare. METHODS We reviewed 104 colorectal cancer patients treated with standard chemotherapy with bevacizumab and examined the incidence of interstitial lung disease and its clinical features. RESULTS We identified interstitial lung(More)
  • 1